LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

RHJ Department of Veterans Affairs, Health Care System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.).